Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption. Denosumab inhibits bone loss; therefore, it is used to treat metabolic bone disea...

Descripción completa

Detalles Bibliográficos

Autores principales:	Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, Bo Shuai
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2023-02-01
Colección:	Frontiers in Oncology
Materias:	denosumab RANK/RANKL/OPG system bone metastasis skeletal-related events osteoclast
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1133828/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!